These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29178353)

  • 1. The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.
    Netterberg I; Karlsson MO; Nielsen EI; Quartino AL; Lindman H; Friberg LE
    Br J Clin Pharmacol; 2018 Mar; 84(3):490-500. PubMed ID: 29178353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.
    Pfeil AM; Vulsteke C; Paridaens R; Dieudonné AS; Pettengell R; Hatse S; Neven P; Lambrechts D; Szucs TD; Schwenkglenks M; Wildiers H
    BMC Cancer; 2014 Mar; 14():201. PubMed ID: 24641830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
    Hansson EK; Friberg LE
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
    Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
    Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment value of interleukin-6, procalcitonin, and C-reactive protein early kinetics for initial antibiotic efficacy in patients with febrile neutropenia: A prospective study.
    Zheng H; Luo Z; Yi Y; Liu K; Huo Z; You Y; Li H; Tang M
    Cancer Med; 2024 Jul; 13(13):e7307. PubMed ID: 38967137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis.
    Wu CW; Wu JY; Chen CK; Huang SL; Hsu SC; Lee MT; Chang SS; Lee CC
    Support Care Cancer; 2015 Oct; 23(10):2863-72. PubMed ID: 25701436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective cohort study of febrile neutropenia in breast cancer patients with neoadjuvant and adjuvant chemotherapy: CSPOR-BC FN study.
    Ishikawa T; Sakamaki K; Narui K; Kaise H; Tsugawa K; Ichikawa Y; Mukai H;
    Jpn J Clin Oncol; 2016 Jul; 46(7):692-5. PubMed ID: 27162322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of Levofloxacin Hydrate in Febrile Neutropenia for Outpatient Chemotherapy].
    Inagaki M; Sato J; Nihei S; Kashiwaba M; Kudo K
    Gan To Kagaku Ryoho; 2016 May; 43(5):593-6. PubMed ID: 27210089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
    Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
    Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.
    Wang L; Barron R; Baser O; Langeberg WJ; Dale DC
    Value Health; 2014 Sep; 17(6):739-43. PubMed ID: 25236998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of the Risk Factors of Febrile Neutropenia Among 72 Women Receiving FEC in Early Breast Cancer Chemotherapy].
    Ishii N; Fujimori T; Kasagawa T; Udagawa I
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1555-1557. PubMed ID: 28133055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10.
    Uys A; Rapoport BL; Fickl H; Meyer PW; Anderson R
    Eur J Cancer Care (Engl); 2007 Nov; 16(6):475-83. PubMed ID: 17944761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.
    Bacrie J; Laurans M; Iorio P; Fourme E; Volters AB; Bozec L; Lerebours F; Dubot C; Bensaoula O; Benzidane B; Pierga JY; Lefeuvre D
    Support Care Cancer; 2018 Dec; 26(12):4097-4103. PubMed ID: 29855772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
    Younis T; Rayson D; Jovanovic S; Skedgel C
    Breast Cancer Res Treat; 2016 Oct; 159(3):425-32. PubMed ID: 27572552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer.
    Goyal RK; Tzivelekis S; Rothman KJ; Candrilli SD; Kaye JA
    Support Care Cancer; 2018 Feb; 26(2):539-548. PubMed ID: 28921379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.
    Sugishita M; Imai T; Kikumori T; Mitsuma A; Shimokata T; Shibata T; Morita S; Inada-Inoue M; Sawaki M; Hasegawa Y; Ando Y
    Breast Cancer; 2016 Mar; 23(2):195-201. PubMed ID: 25008867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Verification on the Predictors for Febrile Neutropenia in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Goto W; Kashiwagi S; Matsuoka K; Iimori N; Kouhashi R; Yabumoto A; Takada K; Asano Y; Tauchi Y; Ogisawa K; Morisaki T; Shibutani M; Tanaka H; Maeda K
    Anticancer Res; 2023 Jan; 43(1):247-254. PubMed ID: 36585206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.